Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting

Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency which is designed to... | May 16, 2023

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,California ,American ,Kate Rausch ,Los Angeles ,Wei Liu ,Chikdu Shivalila ,Chandra Vargeese ,Pachamuthu Kandasamy ,Prashant Monian ,Nasdaq ,Wave Life Sciences Nasdaq ,Biology At Wave Life Sciences ,Exchange Commission ,Wave Life Sciences Ltd ,Medicinal Chemistry At Wave Life Sciences ,American Society ,Wave Life Sciences ,Life Sciences ,Cell Therapy ,Annual Meeting ,Chief Technology Officer ,Wave Life ,Senior Scientist ,Acid Therapeutics ,Oral Abstract ,Vice President ,Medicinal Chemistry ,Poster Session ,Investor Relations ,Private Securities Litigation Reform Act ,Annual Report ,Wave Life Sciences Ltd Stock Exchange ,News ,Information ,Press Release ,Presentations ,Nclude ,Few ,Data ,Showing ,Mproved ,Markers ,F ,Liver ,Disease ,N ,Us ,Na ,Editing ,Herapeutic ,Or ,Ntitrypsin ,Deficiency ,Which ,Esigned Wve Sg9999014716 ,